FierceBiotech 2026年4月23日 Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec
FierceBiotech 2026年4月23日 From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree
FierceBiotech 2026年4月22日 Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials
FierceBiotech 2026年4月20日 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech 2026年4月9日 Roche takes 'leap of faith' with $20M bet on C4T’s antibody-targeted protein degraders
FierceBiotech 2026年3月20日 Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
FierceBiotech 2026年3月10日 Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead
FierceBiotech 2026年3月9日 Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
FierceBiotech 2026年3月6日 Setting a new bar? Zealand touts 'placebo-like tolerability' for Roche-partnered weight loss drug
FierceBiotech 2026年3月4日 Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem'
FierceBiotech 2026年1月29日 Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
FierceBiotech 2026年1月9日 Roche returns to MediLink with promise of $570M near-term payments for another ADC
FierceBiotech 2025年12月10日 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
FierceBiotech 2025年12月4日 Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche’s Flatiron